Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Disease Landscape and Forecast | G7 | 2016
Multiple label expansions of premium-priced agents and the launch of seven novel therapies will fuel the significant growth of the NHL market over the ten-year forecast period. The biosimilar erosion expected for rituximab, the patient share and sales leader of 2015 in the NHL space, as well as the generic erosion of lenalidomide (and to a lesser extent bendamustine), will temper the overall growth of this market. Untapped clinical and commercial potential remains in NHL for therapies with improved efficacy and for agents positioned in patient segments that are currently underserved.
Questions Answered:
- Kinase inhibitors have changed the NHL treatment algorithm since their recent approval. Which other kinase inhibitors are most promising in NHL, and what patient populations will they target? What will be their impact to the NHL market?
- Rituxan/MabThera is widely used across all NHL drug-treated populations and garners significant sales. How will market share for rituximab change over our ten-year forecast period as a result of biosimilars? Will Gazyva/Gazyvaro achieve the same status as Rituxan/MabThera within the NHL space, and thus minimize the impact of biosimilar erosion of branded rituximab?
- The NHL market will experience robust growth through 2025. What factors are driving this growth? Which drug class will dominate the treatment of NHL? What new classes of agents will emerge over the ten-year forecast period, and what will be their market impact?
Scope:
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 22 country-specific interviews with experts and 213 country-specific surveys with hematologist-oncologists treating NHL.
Epidemiology: Diagnosed incidence for FL (including transformed FL), CLL/SLL, DLBCL, and MCL.
Population segments in market forecast: First line, second line, and third line for FL, CLL/SLL, DLBCL, and MCL.
Emerging therapies: Phase I and II: 39 drugs; Phase III: 6 drugs; preregistration: 0 drugs; registered: 0 drugs.
